Literature DB >> 25176495

A ten year analysis of the traumatic maxillofacial and brain injury patient in Amsterdam: complications and treatment.

Erik G Salentijn1, John D Collin2, Paolo Boffano3, Tymour Forouzanfar3.   

Abstract

Maxillofacial trauma is often associated with injuries to the cranium, especially in high-energy trauma. The management of such cases can be challenging and requires close cooperation between oral and maxillofacial surgery and neurosurgical teams. There are few reports in the current literature describing the complications that develop in patients with maxillofacial trauma and traumatic brain injury (TBI). Complications can be categorized as early or late and/or minor and major. The exact definition of complications and their categorization remains a matter of current debate. We present a 10 year retrospective study of complications and their subsequent management in patients receiving maxillofacial and neurosurgical treatment for maxillofacial trauma associated with TBI. The study population consisted of 47 people, excluded from a maxillofacial trauma population of 579 patients. The severity of the trauma was scored as mild, moderate or severe, using the Glasgow Coma Scale at presentation of the Emergency Department. In total 36 patients (76.6%) developed complications. Patients involved in road traffic collision were most likely to develop complications (92.3%). This was followed by falls (66.7%) as mechanism of the injury. Patients aged 60-69 years experienced the highest complication rate (5), followed by patients aged 20-29 years (4.1) and 30-39 years (3.5). The majority of complications were infection and inflammation (36.4%), followed by neurological deficit (24.0%), physiological dysregulation (11.6%) and facial bone deformity (8.3%). Patients who developed no complications, most often presented with mild TBI (72.7%). The most common treatment modality employed to manage complications was pharmacological, followed by antibiotic treatment, conservative treatment and decompression therapy. The mean hospital stay after the trauma for the patients with complications was 28 days. Thirteen patients (36.1%) were transferred to a rehabilitation centre, a nursing home, or a home for the elderly. Nine patients (25%) completely recovered from their complications and 4 patients (11.1%) died after the trauma. This report provides useful data concerning the rate and type of complications that occur, and the multidisciplinary treatment that is required in traumatic maxillofacial and brain injury patients.
Copyright © 2014 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Brain; Complications; Injury; Maxillofacial; Trauma; Treatment

Mesh:

Year:  2014        PMID: 25176495     DOI: 10.1016/j.jcms.2014.06.005

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  4 in total

1.  A retrospective cohort study on the aetiology and characteristics of maxillofacial fractures presenting to a tertiary centre in the UK.

Authors:  Munir Abukhder; Dima Mobarak
Journal:  Ann Med Surg (Lond)       Date:  2022-04-12

2.  Maxillofacial fractures and craniocerebral injuries - stress propagation from face to neurocranium in a finite element analysis.

Authors:  Heike Huempfner-Hierl; Andreas Schaller; Thomas Hierl
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2015-04-21       Impact factor: 2.953

3.  The use of reformatted Cone Beam CT images in assessing mid-face trauma, with a focus on the orbital floor fractures.

Authors:  Raluca Roman; Mihaela Hedeşiu; Floarea Fildan; Robert Ileşan; Diana Mitea; Cristian Dinu; Mihaela Băciuţ
Journal:  Clujul Med       Date:  2016-10-20

4.  Radiographic evaluation of percutaneous transfacial wiring versus open internal fixation for surgical treatment of unstable zygomatic bone fractures.

Authors:  Guillaume Giran; Arnaud Paré; Benjamin Croisé; Carine Koudougou; Jacques Marie Mercier; Boris Laure; Pierre Corre; Hélios Bertin
Journal:  PLoS One       Date:  2019-08-15       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.